search
Back to results

Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1

Primary Purpose

Cocaine-Related Disorders

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Risperidone
Sponsored by
Butler Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring cocaine abuse, cocaine addiction

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Please contact site for information.

Sites / Locations

  • Brown University School of Medicine

Outcomes

Primary Outcome Measures

Analog mood scales
POMS
EPS sx

Secondary Outcome Measures

Full Information

First Posted
September 20, 1999
Last Updated
July 23, 2015
Sponsor
Butler Hospital
Collaborators
National Institute on Drug Abuse (NIDA), VA Boston Healthcare System
search

1. Study Identification

Unique Protocol Identification Number
NCT00000309
Brief Title
Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1
Official Title
Serotonin/Dopamine Antagonism of Cocaine Effect
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Terminated
Why Stopped
Unable to recruit adequate number of subjects
Study Start Date
August 1994 (undefined)
Primary Completion Date
January 2000 (Actual)
Study Completion Date
January 2000 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Butler Hospital
Collaborators
National Institute on Drug Abuse (NIDA), VA Boston Healthcare System

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders
Keywords
cocaine abuse, cocaine addiction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Masking
Double
Allocation
Randomized
Enrollment
0 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Risperidone
Primary Outcome Measure Information:
Title
Analog mood scales
Title
POMS
Title
EPS sx

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lawrence Price, M.D.
Organizational Affiliation
Brown University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brown University School of Medicine
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
2906
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1

We'll reach out to this number within 24 hrs